Device Trial Radar · NCT07005232
Lead Evaluation for Defibrillation and Reliability Post Approval Study
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
2,000
Planned (sponsor's estimate)
Start
Jan 7, 2026
Primary completion
Sep 2032
Study completion Sep 2032
Sponsor
- Lead sponsor
- MedtronicPublic (MDT)
- Sponsor type
- Industry
- First posted
- Jun 5, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Medtronic is sponsoring the LEADR PAS to provide continuing evaluation and periodic reporting of safety and effectiveness of the OmniaSecure™ defibrillation lead following commercial release. The LEADR PAS is conducted within Medtronic's Product Surveillance Registry Platform (NCT01524276).
Conditions
- Tachyarrhythmia
Interventions
defibrillation leadDevice
This is a device registry for the OmniaSecure™ defibrillation lead. The OmniaSecure lead is a steroid eluting, integrated bipolar, nonretractable screw-in, catheter delivered, transvenous ventricular lead with a Right Ventricular (RV) defibrillation coil electrode. The lead is designed for pacing, sensing, cardioversion, and defibrillation therapies, and has application for patients whom transvenous ICDs and cardiac resynchronization therapy defibrillators (CRT-Ds) are indicated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complication Survival RateTime frame: 5 years
Locations
97 sites in 9 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama
Southwest EP Clinic
Chandler, Arizona
Saint Vincent Heart Clinic Arkansas
Little Rock, Arkansas
94 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.